Overall rank by patents
#33,501
Across all tracked assignees
USPTO PatentsView assignee record - 8 granted patents across 7 technology areas, active 2016–2021. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
The verdict
Tagcyx holds 8 US patents across 7 technology areas, rank #33,501 of 50,000 tracked assignees.
Tagcyx Biotechnologies Inc. has been granted 8 US utility patents between 2016 and 2021, placing Tagcyx Biotechnologies Inc. at rank #33,501 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 5.3 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Tagcyx Biotechnologies Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Tagcyx sits between T6 Health Systems Llc (8 patents, rank #33,497) and Taiwan Chelic Co., Ltd. (8 patents, rank #33,505) - the closest US assignees by grant volume. The composite Innovation Score of 20.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 4 in the 2015–2019 window, a +0% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Tagcyx Biotechnologies Inc.'s 5.3 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Tagcyx Biotechnologies Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
T6 Health Systems LLC
8 patents
TABATA CO., LTD.
8 patents
TACHIKAWA CORPORATION
8 patents
TACTILE DISPLAYS, LLC
8 patents
TAGORE TECHNOLOGY, INC.
8 patents
TAIDOC TECHNOLOGY CORPORATION
8 patents
TAIFLEX Scientific Co., Ltd.
8 patents
TAIWAN CHELIC CO., LTD.
8 patents
TAGCYX Biotechnologies Inc.
8 patents
What this shows Tagcyx holds 8 patents at rank #33,501, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #33,501 in granted patent volume.
Other assignees with the most granted patents in Tagcyx's primary technology class.
Tagcyx's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
20 Top 93% higher than 7% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 12.5% |
| 2017 | 1 | 12.5% |
| 2018 | 2 | 25.0% |
| 2020 | 3 | 37.5% |
| 2021 | 1 | 12.5% |
Top 7 of 7 technology areas
Overall rank by patents
#33,501
Across all tracked assignees
20.1 out of 100
How to use this portfolio
Tagcyx's 8 grants land it in the top 93% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.